Difference between revisions of "Envafolimab (Enweida)"
Jump to navigation
Jump to search
m |
m |
||
| Line 11: | Line 11: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| + | *[[Colorectal cancer, MSI-H or dMMR|dMMR colorectal cancer]] | ||
*[[MSI-H or dMMR|MSI-H or dMMR solid tumors (tissue-agnostic)]] | *[[MSI-H or dMMR|MSI-H or dMMR solid tumors (tissue-agnostic)]] | ||
==History of changes in NMPA indication== | ==History of changes in NMPA indication== | ||
| − | *2021-11-26: Approved for adult patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced solid tumors | + | *2021-11-26: Approved for adult patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced solid tumors who have experienced disease progression following prior treatment and have no satisfactory alternative treatment options. |
| + | *2021-11-26: Approved for adult patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced colorectal cancer who have experienced disease progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. | ||
==Also known as== | ==Also known as== | ||
Revision as of 14:10, 5 June 2023
Note: Envafolimab is approved in China, but does not appear to have a brand name at this time.
General information
Class/mechanism: PD-L1 antibody.
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Toxicity management
Diseases for which it is used
History of changes in NMPA indication
- 2021-11-26: Approved for adult patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced solid tumors who have experienced disease progression following prior treatment and have no satisfactory alternative treatment options.
- 2021-11-26: Approved for adult patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced colorectal cancer who have experienced disease progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.
Also known as
- Code name: KN 035